Method for establishing non-human primate animal model of parkinson disease by lateral ventricle administration of MPP<+>

Abstract

A method for establishing a non-human primate animal model of parkinson disease by lateral ventricle administration of MPP<+> belongs to the biomedical technology. The method comprises the following steps: 1, preparing a lateral ventricle administration device; 2, according to a monkey brain atlas and nuclear magnetic resonance imaging data, acquiring a positioning coordinate of a lateral ventricle; 3, inserting a catheter into a lateral ventricle administration position through a monkey stereotaxic instrument, and beginning to administrate the drug after 5-8 days after the animal recovers; injecting a physiological saline solution containing MPP<+> into the lateral ventricle by an injector connected with the tail end of an administration pipe, with the MPP<+> concentration of 0.5-0.7 mg / mL and each administration dosage of 0.1-0.3 mL; carrying out administration one time every 48-72 hours, and after administration for 30-60 days, establishing the non-human primate animal model of the parkinson disease. The method employs a new administration mode that the MPP<+> (1-methyl-4-phenylpyridinium iodide) drug is directly injected into the lateral ventricle of the animal for modeling. With lateral ventricle injection, MPP<+> can perform whole brain circulation together with cerebrospinal fluid to specifically damage dopamine neurons in a brain and cause symptoms of the parkinson disease, and can furthest avoid toxic and side effects of the drug on a periphery.

Description

technical field [0001] The invention belongs to biomedical technology, and in particular relates to a method for establishing an animal model. Background technique [0002] For many years, non-human primates (such as macaques, crab-eating monkeys, etc.) have been ideal objects for establishing animal models of Parkinson's disease. The commonly used modeling methods mainly use MPTP (1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine) intravenous infusion, intramuscular injection or carotid artery one-time administration to establish animal models of chronic or acute Parkinson's disease. Although these methods can induce typical behavioral symptoms of Parkinson's disease, there are obvious disadvantages. A review of animal models of Parkinson's published by M. Gerlach and P. Riederer concluded the following points: Animals during the modeling period showed large individual differences, animals were subject to drug-induced toxic side effects, and behavioral symptoms Unstable, with...

AI Technical Summary

Problems solved by technology

Due to MPP + It cannot pass through the blood-brain barrier, so it is difficult for traditional drug delivery methods to MPP + into the central nervous system